These findings contrast with studies on PPARγ agonists in AD, where chronic treatment with pioglitazone, a PPARγ agonist, reduces Aβ oligomer neurotoxicity by promoting Aβ fibril formation 79. Here, PPARG is linked to Alzheimer disease.